# GLOASIS (NCT06558604)

> Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma

No report yet. It can be ordered.

- Drugs tested: glofitamab plus venetoclax plus obinutuzumab; glofitamab plus venetoclax plus zanubrutinib plus obinutuzumab
- Indication: high-risk mantle-cell lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06558604
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: The Lymphoma Academic Research Organisation
- Conditions: Lymphoma, Mantle-Cell
- Interventions: Obinutuzumab; Glofitamab; Venetoclax Oral Product; Zanubrutinib Oral Capsule
- Enrollment: 100
- Primary outcome: PFS at the end of C17 (each cycle is 21 days)

## Indexed commentary on GLOASIS so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 YouTube videos
- 1 post on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=gloasis-nct06558604